Ipsen appoints Josep Catllà as EVP, Chief Corporate Affairs Officer
June 06 2024 - 8:30AM
Ipsen appoints Josep Catllà as EVP, Chief Corporate Affairs
Officer
PARIS, FRANCE, 06 June 2024 -
Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven
biopharmaceutical company, announced today the appointment of Josep
Catllà as EVP, Chief Corporate Affairs Officer, effective August
19, 2024. He will serve on the Executive Leadership Team (ELT) and
report directly to Ipsen’s Chief Executive Officer (CEO), David
Loew.
“We are thrilled to welcome Josep to Ipsen as
our new Chief Corporate Affairs Officer, as h. He brings years of
experience inof communications and public affairs and a proven
track record of developing corporate affairs leaders. His focus on
patient care and sustainability and his strategic vision will be
instrumental to fosterin fostering employee engagement and
partnership with stakeholders while reinforcing Ipsen’s culture of
collaboration and excellence,” said David Loew, CEO, Ipsen.
Josep joins Ipsen from Sanofi, where he has
spent the last 14 years in leadership positions at country, region
and corporate levels. Over the last four years he has been serving
in a similar position, served as Head of Corporate Affairs,
reporting to Sanofi’s CEO. In addition to running Communications
and Public Affairs, he built a robust sustainability strategy.
Josep brings 30 years of experience in the world
of communications and public affairs and government relations,
starting his career at the European Commission in Brussels in the
early 1990s and leading the European Public Affairs practice of
Weber Shandwick in Brussels, and then running Weber Shandwick Spain
& and Portugal, before joining the pharmaceutical industry.
“I am incredibly excited to join Ipsen’s
Executive Leadership Team and to lead the corporate affairs
function as Ipsen continues to deliver innovative medicines to
patients around the world. I am encouraged by the transformation
and evolution of the company, building on their long history and
legacy. I look forward to working with patient communities and
alongside policymakers, media, and other partners to deliver on
Ipsen’´s mission on a sustainable manner, while embarking our
employees into this fascinating journey of improving people´s
lives,” said Josep Catllà.
Gwenan White, EVP, Communications, External
Affairs & Sustainability for the last three years, will leave
Ipsen to pursue other opportunities. The Company wishes Gwenan
every success in her future endeavors and would like to thank her
for her leadership.
ENDS
About Ipsen
We are a global biopharmaceutical company with a
focus on bringing transformative medicines to patients in three
therapeutic areas: Oncology, Rare Disease and Neuroscience.
Our pipeline is fueled by external innovation
and supported by nearly 100 years of development experience and
global hubs in the U.S., France and the U.K. Our teams in more than
40 countries and our partnerships around the world enable us to
bring medicines to patients in more than 80 countries.
Ipsen is listed in Paris (Euronext: IPN) and in
the U.S. through a Sponsored Level I American Depositary Receipt
program (ADR: IPSEY). For more information, visit ipsen.com.
Ipsen contacts
Investors
- Craig
Marks | craig.marks@ipsen.com
- Nicolas
Bolger | nicolas.bogler@ipsen.com
Media
- Amy Wolf
| amy.wolf@ipsen.com
- Ioana
Piscociu | ioana.piscociu@ipsen.com
Disclaimers and/or Forward-Looking
StatementsThe forward-looking statements, objectives and
targets contained herein are based on Ipsen’s management strategy,
current views and assumptions. Such statements involve known and
unknown risks and uncertainties that may cause actual results,
performance or events to differ materially from those anticipated
herein. All of the above risks could affect Ipsen’s future ability
to achieve its financial targets, which were set assuming
reasonable macroeconomic conditions based on the information
available today. Use of the words ‘believes’, ‘anticipates’ and
‘expects’ and similar expressions are intended to identify
forward-looking statements, including Ipsen’s expectations
regarding future events, including regulatory filings and
determinations. Moreover, the targets described in this document
were prepared without taking into account external-growth
assumptions and potential future acquisitions, which may alter
these parameters. These objectives are based on data and
assumptions regarded as reasonable by Ipsen. These targets depend
on conditions or facts likely to happen in the future, and not
exclusively on historical data. Actual results may depart
significantly from these targets given the occurrence of certain
risks and uncertainties, notably the fact that a promising medicine
in early development phase or clinical trial may end up never being
launched on the market or reaching its commercial targets, notably
for regulatory or competition reasons. Ipsen must face or might
face competition from generic medicine that might translate into a
loss of market share. Furthermore, the research and development
process involves several stages each of which involves the
substantial risk that Ipsen may fail to achieve its objectives and
be forced to abandon its efforts with regards to a medicine in
which it has invested significant sums. Therefore, Ipsen cannot be
certain that favorable results obtained during preclinical trials
will be confirmed subsequently during clinical trials, or that the
results of clinical trials will be sufficient to demonstrate the
safe and effective nature of the medicine concerned. There can be
no guarantees a medicine will receive the necessary regulatory
approvals or that the medicine will prove to be commercially
successful. If underlying assumptions prove inaccurate or risks or
uncertainties materialize, actual results may differ materially
from those set forth in the forward-looking statements. Other risks
and uncertainties include but are not limited to, general industry
conditions and competition; general economic factors, including
interest rate and currency exchange rate fluctuations; the impact
of pharmaceutical industry regulation and healthcare legislation;
global trends toward healthcare cost containment; technological
advances, new medicine and patents attained by competitors;
challenges inherent in new-medicine development, including
obtaining regulatory approval; Ipsen’s ability to accurately
predict future market conditions; manufacturing difficulties or
delays; financial instability of international economies and
sovereign risk; dependence on the effectiveness of Ipsen’s patents
and other protections for innovative medicines; and the exposure to
litigation, including patent litigation, and/or regulatory actions.
Ipsen also depends on third parties to develop and market some of
its medicines which could potentially generate substantial
royalties; these partners could behave in such ways which could
cause damage to Ipsen’s activities and financial results. Ipsen
cannot be certain that its partners will fulfil their obligations.
It might be unable to obtain any benefit from those agreements. A
default by any of Ipsen’s partners could generate lower revenues
than expected. Such situations could have a negative impact on
Ipsen’s business, financial position or performance. Ipsen
expressly disclaims any obligation or undertaking to update or
revise any forward-looking statements, targets or estimates
contained in this press release to reflect any change in events,
conditions, assumptions or circumstances on which any such
statements are based, unless so required by applicable law. Ipsen’s
business is subject to the risk factors outlined in its
registration documents filed with the French Autorité des
Marchés Financiers. The risks and uncertainties set out are not
exhaustive and the reader is advised to refer to Ipsen’s latest
Universal Registration Document, available on ipsen.com.
- Ipsen PR_Josep Catlla Appointment_06062024
- Josep Catllà
Ipsen (EU:IPN)
Historical Stock Chart
From Sep 2024 to Oct 2024
Ipsen (EU:IPN)
Historical Stock Chart
From Oct 2023 to Oct 2024